Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07599696 · ClinicalTrials.gov registry record · NA
Speech Amplification Devices for Parkinson Disease: Talker- and Technology-Driven Enhancements
A NA study, sponsored by Michigan State University.
- Recruiting
- Registry status
- NA
- Development phase
- 100
- Enrollment target
NCT07599696: Recruiting NA study, sponsored by Michigan State University.
NCT07599696 is a NA study that is actively recruiting participants, run by Michigan State University. The registered enrollment target is 100 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07599696, a NA study, is actively recruiting participants, sponsored by Michigan State University.
- RECRUITING
- Registry status
- NA
- Development phase
- 100 participants
- Enrollment target
Study Summary
The proposed research aims to investigate the use of speech amplification devices as a potential treatment option for people with Parkinson's disease and related disorders who exhibit hypophonia, a voice disorder that affects over half of those with Parkinson's disease. By characterizing the acoustic and perceptual effects of speech amplification and identifying ways to optimize outcomes through talker- and device-specific enhancements, this project seeks to develop personalized, evidence-based treatment options for hypophonia. The current proposal will move this effort forward by systematically eliciting and modifying speech amplification device output that leverage both behavioral and technological approaches.
Primary Outcome
Decibel sound pressure level (dB SPL) measured from speech audio recordings
Interventions
- BEHAVIORAL Behavioral speech strategies + speech amplification
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2024-03-01 |
| Est. Completion | 2028-05-31 |
| Phase | NA |
What NCT07599696 shows while recruiting
NCT07599696 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 1 intervention - of which Behavioral speech strategies + speech amplification is the first listed.
NCT07599696 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07599696 about?
NCT07599696 is a clinical study titled "Speech Amplification Devices for Parkinson Disease: Talker- and Technology-Driven Enhancements". The proposed research aims to investigate the use of speech amplification devices as a potential treatment option for people with Parkinson's disease and related disorders who exhibit hypophonia, a voice disorder that affects over half of those with Parkinson's disease. By characterizing the acousti...
What is the current status of trial NCT07599696?
This trial is currently recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2024-03-01. Estimated completion is 2028-05-31.
What interventions are being tested in trial NCT07599696?
The interventions under investigation include: Behavioral speech strategies + speech amplification (BEHAVIORAL).
Who is sponsoring clinical trial NCT07599696?
This trial is sponsored by Michigan State University, which has 120 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07599696's enrollment target sits among peer trials
100 840th of 2000 higher than 1,081 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI